See more : Concord International Securities Co., Ltd (5864.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Madrigal Pharmaceuticals, Inc. (MDGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Madrigal Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Partner Communications Company Ltd. (PTNR.TA) Income Statement Analysis – Financial Results
- Centrica plc (CNA.L) Income Statement Analysis – Financial Results
- AB Volvo (publ) (VOLVB.PR) Income Statement Analysis – Financial Results
- Acusphere, Inc. (ACUS) Income Statement Analysis – Financial Results
- M&T Bank Corporation (MTB-PH) Income Statement Analysis – Financial Results
Madrigal Pharmaceuticals, Inc. (MDGL)
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 147.00K | 7.58M | 14.80M | 144.25M | 2.62M | 743.00K | 0.00 | 0.00 | 173.00K | 1.30M | 0.00 | 0.00 |
| Cost of Revenue | 527.00K | 467.00K | 405.00K | 471.00K | 112.00K | 96.00K | 77.00K | 156.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -527.00K | -467.00K | -405.00K | -471.00K | -112.00K | -96.00K | -77.00K | -156.00 | 0.00 | 0.00 | 0.00 | 147.00K | 7.58M | 14.80M | 144.25M | 2.62M | 743.00K | 0.00 | 0.00 | 173.00K | 1.30M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 272.35M | 245.44M | 205.16M | 184.81M | 72.32M | 25.39M | 24.39M | 15.93M | 54.22M | 68.21M | 71.86M | 49.41M | 41.46M | 40.25M | 51.05M | 81.58M | 52.03M | 50.50M | 59.90M | 38.14M | 24.34M | 7.29M | 277.00K |
| General & Administrative | 108.15M | 48.13M | 37.32M | 21.86M | 22.65M | 15.29M | 7.67M | 9.29M | 13.39M | 15.75M | 15.70M | 11.68M | 11.55M | 11.45M | 12.65M | 14.74M | 14.93M | 8.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 108.15M | 48.13M | 37.32M | 21.86M | 22.65M | 15.29M | 7.67M | 9.29M | 13.39M | 15.75M | 15.70M | 11.68M | 11.55M | 11.45M | 12.65M | 14.74M | 14.93M | 8.65M | 11.28M | 7.38M | 5.26M | 0.00 | 124.00K |
| Other Expenses | 0.00 | 0.00 | 273.00K | 100.00K | 0.00 | 200.00K | 350.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 380.50M | 293.57M | 242.48M | 206.67M | 94.97M | 40.68M | 32.06M | 25.22M | 67.61M | 83.95M | 87.56M | 61.09M | 53.02M | 51.70M | 63.71M | 96.32M | 66.96M | 59.15M | 71.18M | 45.52M | 29.60M | 7.29M | 401.00K |
| Cost & Expenses | 380.50M | 293.57M | 242.48M | 206.67M | 94.97M | 40.68M | 32.06M | 25.22M | 67.61M | 83.95M | 87.56M | 61.09M | 53.02M | 51.70M | 63.71M | 96.32M | 66.96M | 59.15M | 71.18M | 45.52M | 29.60M | 7.29M | 401.00K |
| Interest Income | 19.58M | 2.19M | 363.00K | 4.33M | 11.02M | 7.67M | 558.00K | 48.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 96.00K | 1.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 12.71M | 3.96M | 0.00 | 0.00 | 11.02M | 7.67M | 558.00K | 1.16M | 1.06M | 2.21M | 2.63M | 1.85M | 1.95M | 569.00K | 312.00K | 489.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 527.00K | 467.00K | 405.00K | 471.00K | 112.00K | 96.00K | 77.00K | 156.00 | 662.00K | 673.00K | 516.00K | 738.00K | 1.46M | 1.93M | 2.46M | 2.72M | 3.35M | 3.66M | 2.46M | 1.55M | 1.01M | 47.06M | 0.00 |
| EBITDA | -379.97M | -293.10M | -242.08M | -206.20M | -94.86M | -40.59M | -31.99M | -22.52M | -3.23M | -83.28M | -87.04M | -60.20M | -43.97M | -34.97M | 81.86M | -90.99M | -62.87M | -53.62M | -71.04M | -43.80M | -27.29M | 10.80M | -401.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -40,954.42% | -579.75% | -236.20% | 58.40% | -3,479.58% | -8,827.19% | 0.00% | 0.00% | -24,977.46% | -2,124.54% | 0.00% | 0.00% |
| Operating Income | -380.50M | -293.57M | -242.48M | -206.67M | -94.97M | -40.68M | -32.06M | -25.22M | -67.61M | -83.95M | -87.56M | -60.94M | -45.43M | -36.90M | 79.30M | -93.71M | -66.22M | -59.15M | -71.18M | -46.93M | -28.29M | -36.26M | -401.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -41,456.46% | -599.05% | -249.26% | 54.98% | -3,583.48% | -8,911.98% | 0.00% | 0.00% | -27,126.59% | -2,169.79% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.87M | -1.78M | 636.00K | 4.43M | 11.02M | 7.87M | 908.00K | -1.16M | 60.77M | -2.21M | -2.63M | -1.85M | -1.95M | -569.00K | -216.00K | 1.09M | 2.72M | 22.00K | 2.32M | -588.00K | 416.00K | -18.09M | 0.00 |
| Income Before Tax | -373.63M | -295.35M | -241.85M | -202.24M | -83.95M | -32.81M | -31.15M | -26.39M | -68.67M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -122.08M | -59.13M | -68.86M | -47.52M | -27.88M | -54.35M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -42,714.29% | -624.74% | -253.10% | 54.83% | -3,541.80% | -16,430.69% | 0.00% | 0.00% | -27,466.47% | -2,137.88% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.96M | -768.00K | -4.80M | -11.14M | 7.87M | -635.00K | -373.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.45M | 0.00 | -2.72M | -1.88M | -2.32M | 588.00K | -416.00K | -18.20M | 381.00K |
| Net Income | -373.63M | -299.31M | -241.08M | -197.44M | -72.81M | -32.81M | -31.15M | -26.39M | -68.67M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -63.50M | -57.27M | -68.86M | -45.93M | -27.88M | -36.15M | -381.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -42,714.29% | -624.74% | -253.10% | 54.83% | -3,541.80% | -8,545.76% | 0.00% | 0.00% | -26,551.45% | -2,137.88% | 0.00% | 0.00% |
| EPS | -19.99 | -17.47 | -14.58 | -12.78 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.55 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 | -105.09 | -4.55 |
| EPS Diluted | -19.99 | -17.47 | -14.58 | -12.78 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.20 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 | -105.09 | -4.55 |
| Weighted Avg Shares Out | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.80M | 12.24M | 5.20M | 171.01K | 2.81M | 2.03M | 1.70M | 1.35M | 1.15M | 968.21K | 963.86K | 927.59K | 636.14K | 635.80K | 534.39K | 624.37K | 344.04K | 83.74K |
| Weighted Avg Shares Out (Dil) | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.80M | 12.24M | 5.20M | 171.01K | 2.81M | 2.03M | 1.70M | 1.35M | 1.15M | 974.81K | 963.86K | 927.59K | 636.14K | 635.80K | 534.39K | 624.37K | 344.04K | 83.74K |
Is Madrigal Pharmaceuticals Stock a Buy?
Madrigal Pharmaceuticals earned an important regulatory approval this year. However, the biotech faces risks, including the need for a post-marketing study.
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
Madrigal Pharmaceuticals is the only company with an approved drug for MASH. Eli Lilly's latest clinical trial data shows that its candidate may perform even better.
Where Will Madrigal Pharmaceuticals Be in 3 Years?
Madrigal Pharmaceuticals currently has undisputed dominance in its main market. There are powerful actors trying to elbow their way in and change that status.
Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked
Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain after Wolfe Research initiated positive coverage. Competition from...
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Madrigal Pharmaceuticals has a monopoly in its main market -- for the moment. Viking Therapeutics has a good candidate, but it could face powerful competitors.
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
CONSHOHOCKEN, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced results from new analyses of the Phase 3 MAESTRO-NASH trial of Rezdiffra being presented...
Is Madrigal Pharmaceuticals Stock a Buy?
Madrigal Pharmaceuticals recently earned an impressive approval from the FDA. The biotech still has work to do to reach its peak potential with this medicine.
Amalgamated Bank Raises Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Amalgamated Bank boosted its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,119 shares of...
Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript
Madrigal Pharmaceuticals (NASDAQ:MDGL ) Q1 2024 Results Conference Call May 7, 2024 8:00 AM ET Company Participants Tina Ventura - Chief IRO Bill Sibold - CEO Mardi Dier - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler Eli Merle...
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today reports first-quarter 2024 financial results and provides corporate updates.
Source: https://incomestatements.info
Category: Stock Reports